Ariana Pelosci

Findings highlighted that increased physical activity was associated with a variety of benefits in improving overall well-being in early adolescent and young adult survivors.

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.

The phase 2 FDZL-001 trial showed high overall survival and progression-free survival rates with camrelizumab plus Nab-POF in patients with gastric/GEJ cancer.

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer.

A nurse practitioner discusses the importance of compassionate end-of-life care discussions.

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary cholangitis, respectively.

Pain management specialists were rarely consulted for cancer-related pain, a recent study showed.

Pelvic transposition may improve quality of life and preserve fertility in patients with gynecologic cancer undergoing pelvic radiation.

Distant relapse-free survival was maintained with non-operative management of pMMR locally advanced rectal cancer.

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine therapy.

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

SON-080, a novel drug, may reduce chemotherapy-induced peripheral neuropathy in patients previously treated with chemotherapy.

Assisted reproductive techniques may be safe for patients with BRCA-mutated breast cancer, according to an ESMO study.

A subgroup analysis of the TRANSCEND NHL 001 trial demonstrated that liso-cel may be more effective in earlier lines of treatment for patients with mantle cell lymphoma.

Adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Tolerable anti-tumor activity was demonstrated in patients with HER2-overexpressing non–small cell lung cancer who were treated with trastuzumab deruxtecan at 2 dose levels.

Patients with triple-negative breast cancer with an increased TIL count in breast tissue were more likely to have an improved distant recurrence-free survival.

Nurse coordinators should aim to transmit information to both the patient and caregiver during outpatient CAR T-cell treatment process.

A subgroup of patients from the 3 CARTITUDE trials experienced cranial nerve palsy after treatment, most of whom were men.

Differences in gut microbiome signatures may lead to more accurate treatments and diagnoses for patients with colorectal cancer.

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.

Patients with non–small cell lung cancer treated with targeted therapies experienced an overall survival benefit.

Compared with placebo, ruxolitinib cream significantly improved body surface area in patients with cutaneous graft-vs-host disease in a phase 2 trial.

Treatment-emergent symptoms were easily resolved after treatment with olaparib for BRCA1/2 high-risk HER2-negative breast cancer, as shown in a patient reported outcome analysis of the phase 3 OlympiA trial.

Nivolumab plus chemotherapy enhanced overall survival and progression-free survival in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

Findings presented at the 2023 San Antonio Breast Cancer Symposium described some possible avenues for artificial intelligence to be useful in breast cancer care.

In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.

Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.

Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.